Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Direct contact with ice or freezing temperatures will destroy peptide structure
It combines BPC157 and TB500 to try to speed up healing from injuries and surgery
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
Multiple independent investigations have identified concerning patterns including fake endorsements, misleading certifications, unauthorized subscription charges, and the absence of clinical evidence
Liraglutide | Drugs BNF NICE
US$ 26.39
US$ 23.35
US$ 21.06
US$ 23.75
